Metabolomics of bronchopulmonary dysplasia: Clinica Chimica Acta

F. Piersigilli, V. Bhandari

Research output: Contribution to journalArticlepeer-review


The pathogenesis of Bronchopulmonary dysplasia (BPD) remains poorly understood. It is a multifactorial disease having a genetic-environmental basis. Although attempts have been made to identify a biomarker, none have been validated for clinical use to date. Metabolomics is a promising field of the “omics technologies” that could allow for better understanding of the pathogenesis and underlying mechanisms of BPD as well as facilitate detection of biomarkers. Identification of these biomarkers would improve diagnosis, identify patients in early disease stages and potentially target intervention. This review focuses on the evidence arising from metabolomics and its interaction with microbiomics and pharmacology with respect to pathogenesis and treatment options for this multifactorial complex disease. © 2019 Elsevier B.V.
Original languageEnglish
Pages (from-to)109-114
Number of pages6
JournalClin. Chim. Acta
Publication statusPublished - 2020


  • Biomarker
  • BPD
  • Lung
  • Metabolomics
  • Microbiomics
  • Preterm infant
  • amino acid metabolism
  • human
  • lipid metabolism
  • lung dysplasia
  • metabolite
  • metabolomics
  • molecular pathology
  • oxidative stress
  • priority journal
  • quantitative analysis
  • respiratory distress syndrome
  • Review
  • metabolism
  • microbiology
  • Bronchopulmonary Dysplasia
  • Humans


Dive into the research topics of 'Metabolomics of bronchopulmonary dysplasia: Clinica Chimica Acta'. Together they form a unique fingerprint.

Cite this